Principles of pharmacodynamics and their applications in veterinary pharmacology

Journal of Veterinary Pharmacology and Therapeutics - Tập 27 Số 6 - Trang 397-414 - 2004
P. Lees1, Fiona Cunningham1, Jonathan Elliott1
1Department of Veterinary Basic Sciences, Royal Veterinary College, Hawkshead Campus, Hatfield, Hertfordshire, UK.

Tóm tắt

Pharmacodynamics (PDs) is the science of drug action on the body or on microorganisms and other parasites within or on the body. It may be studied at many organizational levels – sub‐molecular, molecular, cellular, tissue/organ and whole body – using in vivo, ex vivo and in vitro methods and utilizing a wide range of techniques. A few drugs owe their PD properties to some physico‐chemical property or action and, in such cases, detailed molecular drug structure plays little or no role in the response elicited. For the great majority of drugs, however, action on the body is crucially dependent on chemical structure, so that a very small change, e.g. substitution of a proton by a methyl group, can markedly alter the potency of the drug, even to the point of loss of activity. In the late 19th century and first half of the 20th century recognition of these facts by Langley, Ehrlich, Dale, Clarke and others provided the foundation for the receptor site hypothesis of drug action. According to these early ideas the drug, in order to elicit its effect, had to first combine with a specific ‘target molecule’ on either the cell surface or an intracellular organelle. It was soon realized that the ‘right’ chemical structure was required for drug–target site interaction (and the subsequent pharmacological response). In addition, from this requirement, for specificity of chemical structure requirement, developed not only the modern science of pharmacology but also that of toxicology. In relation to drug actions on microbes and parasites, for example, the early work of Ehrlich led to the introduction of molecules selectively toxic for them and relatively safe for the animal host.

In the whole animal drugs may act on many target molecules in many tissues. These actions may lead to primary responses which, in turn, may induce secondary responses, that may either enhance or diminish the primary response. Therefore, it is common to investigate drug pharmacodynamics (PDs) in the first instance at molecular, cellular and tissue levels in vitro, so that the primary effects can be better understood without interference from the complexities involved in whole animal studies.

When a drug, hormone or neurotransmitter combines with a target molecule, it is described as a ligand. Ligands are classified into two groups, agonists (which initiate a chain of reactions leading, usually via the release or formation of secondary messengers, to the response) and antagonists (which fail to initiate the transduction pathways but nevertheless compete with agonists for occupancy of receptor sites and thereby inhibit their actions). The parameters which characterize drug receptor interaction are affinity, efficacy, potency and sensitivity, each of which can be elucidated quantitatively for a particular drug acting on a particular receptor in a particular tissue. The most fundamental objective of PDs is to use the derived numerical values for these parameters to classify and sub‐classify receptors and to compare and classify drugs on the basis of their affinity, efficacy, potency and sensitivity.

This review introduces and summarizes the principles of PDs and illustrates them with examples drawn from both basic and veterinary pharmacology. Drugs acting on adrenoceptors and cardiovascular, non‐steroidal anti‐inflammatory and antimicrobial drugs are considered briefly to provide a foundation for subsequent reviews in this issue which deal with pharmacokinetic (PK)–PD modelling and integration of these drug classes. Drug action on receptors has many features in common with enzyme kinetics and gas adsorption onto surfaces, as defined by Michaelis–Menten and Langmuir absorption equations, respectively. These and other derived equations are outlined in this review. There is, however, no single theory which adequately explains all aspects of drug–receptor interaction. The early ‘occupation’ and ‘rate’ theories each explain some, but not all, experimental observations. From these basic theories the operational model and the two‐state theory have been developed. For a discussion of more advanced theories see Kenakin (1997).

Từ khóa


Tài liệu tham khảo

10.1016/S0924-8579(00)00142-4

10.1046/j.1365-2885.2002.00399.x

10.1128/AAC.47.2.626-635.2003

10.1016/S0034-5288(03)00005-5

Ariens E.J., 1954, Affinity and intrinsic activity in the theory of competitive inhibition, Archives Internationale Pharmacodynamie Therapie, 99, 32

10.1016/S0014-2999(98)00520-2

Benz F.W., 1997, Textbook of Ocular Pharmacology

Benz F.W., 1997, Textbook of Ocular Pharmacology

10.1016/S0140-6736(62)90103-4

10.1098/rspb.1983.0093

Clark A.J., 1937, Heffner's Handbuch der Experimentellen Pharmacologie Erganzungsband, Band 4, 38

10.1113/jphysiol.1906.sp001148

Ebert S.C., 1995, Handbook of Pharmacokinetic/Pharmacodynamic Correlation, 35

10.1002/cber.19090420105

10.1046/j.1365-2885.1998.00106.x

Giraudel J.M., 2004, Development of in vitro assays for the evaluation of cyclooxygenase inhibitors and application for predicting the selectivity of NSAIDs in the cat, American Journal of Veterinary Research

10.2746/042516402776249056

Kenakin T., 1997, Pharmacologic Analysis of Drug–Receptor Interaction

10.1016/S0924-8579(02)00025-0

10.1111/j.1365-2885.2004.00618.x

Lees P., 2004, PK‐PD modelling: an alternative to dose titration studies for antimicrobial drug dosage selection, Regulatory Affairs Journal, 15, 1

10.1111/j.1365-2885.2004.00603.x

10.1124/pr.55.4.4

Nolting A., 1995, Handbook of Pharmacokinetic/Pharmacodynamic Correlation, 363

10.1098/rspb.1961.0020

10.1111/j.1476-5381.1956.tb00006.x

10.1046/j.1365-2885.2001.00303.x

10.1016/S0034-5288(02)00039-5

Toutain P.L., 2003, Pharmacokinetics/pharmacodynamics integration in dosage regimen optimisation for veterinary medicine, Journal of Veterinary Pharmacology and Therapeutics, 26, 1

10.1111/j.1365-2885.2004.00613.x

10.1002/jps.2600751108

10.1007/BF01062551